 Role interferons therapy melanoma range potent immunoregulatory molecules cytokines available therapy human melanoma cytokines interferons IFN great depth therapy melanoma IFN able host effector cell function tumor cytolytic function lymphocytes monocytes IFN capacity distribution immunoregulatory expression tumor cell surface class II products major histocompatibility locus activities IFN early application treatment human melanoma empirical evidence IFN exerts significant anti-tumor effects melanoma status adjuvant trials IFN alpha gamma New indirect host-mediated anti-tumor activities IFN opportunity meaningful anti-tumor activity advanced disease adjuvant settings dose ranges toxic conventional maximal tolerable hand cooperative groups Eastern Cooperative Oncology Group ECOG Cancer Leukemia Group CALGB South West Oncology Group SWOG IFN gamma pursuit goal advanced adjuvant settings melanoma tumors determination clinical role IFN biologic response modifiers equal commitment clinical assessment immunobiologic mechanisms anti-tumor effects immunologic assessment IFN number cytokines major focus Pittsburgh Cancer Institute Regional delivery cytokines appropriate toxic approach half-life Regional therapy intralesional route activity range biologics bacillus Calmette-Guerin BCG tumor necrosis factor TNF Intralymphatic therapy methanol extraction residue BCG MER-BCG trials progress optimal dosage route likely optimal role IFN cytokines combination different biologic modalities monoclonal antibodies vaccines expansion activity desired effector cell populations host Enhanced host toxicities anti-tumor effects special attention optimal sequence administration therapeutic index